Date: Monday, November 6, 2017
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Conclusion: The cost per responder favored SC abatacept in patients with seropositive, erosive early RA. Cost savings can be achieved through the use of abatacept over adalimumab in patients with early, rapidly progressing RA in the US, Germany, Spain and Canada.
To cite this abstract in AMA style:Foo J, Rodriguez Heredia J, Polanco Sánchez C, Mtibaa M, Herrmann K, Alemao E, Postema R, Baerwald C. Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cost-per-response-for-abatacept-versus-adalimumab-in-patients-with-seropositive-erosive-early-rheumatoid-arthritis-in-the-us-germany-spain-and-canada/. Accessed June 2, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-per-response-for-abatacept-versus-adalimumab-in-patients-with-seropositive-erosive-early-rheumatoid-arthritis-in-the-us-germany-spain-and-canada/